STOCKHOLM, March 20, 2023 /PRNewswire/ — BioArctic AB’s (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ) protofibril[1] antibody lecanemab (generic name, U.S….
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.